Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DB-1311 |
Synonyms | |
Therapy Description |
DB-1311 is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody conjugated to the topoisomerase inhibitor P1021, which potentially decreases growth of B7-H3 (CD276)-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2967). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DB-1311 | DB 1311|DB1311 | CD276 Antibody 16 | DB-1311 is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody conjugated to the topoisomerase inhibitor P1021, which potentially decreases growth of B7-H3 (CD276)-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2967). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |